SG Power Limited, a longstanding independent power producer (IPP) in Pakistan, has officially finalized its transition into the healthcare sector. The company confirmed in a Monday notice to the Pakistan Stock Exchange (PSX) that the Securities and Exchange Commission of Pakistan (SECP) has formally registered its new principal business line as "pharmaceutical allied."
This transition marks a major milestone in the company’s strategic transformation, moving away from its traditional focus on power generation. With the regulatory framework now in place, SG Power is authorized to engage in a comprehensive range of activities, including the manufacturing, importing, exporting, and distribution of medical devices, hospital supplies, and pharmaceutical products. The company’s scope also extends to the installation, maintenance, and after-sales servicing of specialized healthcare equipment.
The shift follows a Special Resolution passed by members during an Extraordinary General Meeting on May 13, 2026. To support this new direction, the company previously announced plans in May 2026 to raise approximately Rs535 million through a rights issue. SG Power aims to use these funds to diversify its revenue streams, invest in new healthcare operations, and build a stronger foundation for long-term growth.
Incorporated in 1994, SG Power Limited had primarily operated as an IPP, supplying electricity to its associated entity, SG Allied Businesses Limited. By entering the pharmaceutical and medical device markets, the firm intends to move beyond its historical power sector roots and capitalize on emerging opportunities within Pakistan's healthcare industry.
